“…This provides a physiological explanation for the downregulation of CAR observed in malignant glioma cells [26] . Downregulation of CAR has similarly been observed in other tumor types, including ovarian cancer [27,28] , melanoma [29] , head and neck cancer [27,[29][30][31][32] , malignant glioma [21] , musculoskeletal tumors [33] , immature osteoblasts [34] , human rhabdomyosarcoma [35] and bladder cancer [5,36] . Similarly, when compared with normal prostate, CAR expression decreased in prostate carcinoma specimens of all Gleason scores [37] .…”